Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED95 of intravenous esketamine for ureteral stent removal
ChiCTR2200062077Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine, sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Inhibition of body movement. Started Jul 2022; status: recruiting.
02
Drugs
esketamine
Beyond the preview
Go deeper on ChiCTR2200062077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062077.